** CREDENTIALED PRESS ONLY **
A media briefing on new safety controlsfor long-acting beta agonists, medications used to treat asthma
--Janet Woodcock, M.D., director, Center for Drug Evaluation and Research (CDER), FDA
--Gerald Dal Pan, M.D., director, Office of Surveillance and Epidemiology, CDER, FDA
--Badrul Chowdhury, M.D., director, Division of Pulmonary and Allergy Products, Office of Drug Evaluation II, CDER, FDA
--Sally Seymour, M.D., deputy director for safety, Division of Pulmonary and Allergy Products, Office of Drug Evaluation II, CDER
Thurs., Feb. 18, 2010, 1:15 p.m. EST
Reporters may participate in a listen-only mode by dialing 888-455-0031 or for international reporters, 1-312-470-0068. The password for all callers is "FDA." A replay of the briefing will be available until Feb. 25 by calling 888-562-2793 or for international reporters, 1-402-998-1450.
CONTACT: Karen Riley, 301-796-4674 (office), email@example.com, or Erica Jefferson, 301-796-4988, firstname.lastname@example.org, both of FDA
/PRNewswire-USNewswire -- Feb. 18/
SOURCE U.S. Food and Drug Administration
Subscribe to our Free Newsletters!
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...View All